MALE CONTRACEPTION

Česká verzia

Authors: MUDr. Jiří Heráček ^1,2; doc. MUDr. Michael Urban ^1,2; MUDr. Vladimír Sobotka ^1,3; MUDr. Martin Lukeš ¹; MUDr. Lukáš Bittner ¹; MUDr. Tomáš Novotný ¹; MUDr. Zdeněk Otava ¹
Authors place of work: Urologická klinika 3. LF UK a FNKVŠrobárova 50, 100 4 Praha 10e-mail: heracek@fnkv. cz ¹; Androgeos - soukromé urologické a andrologické centrum, Praha ²; Pronatal - centrum asistované reprodukce, Praha ³
Published in the journal: Urol List 2007; 5(3): 26-33

Summary

The growth of world population and its impact on the environment and economy, especially in the developing countries, has brought about the need for family planning assistance available to everyone. Health organisations and pharmaceutical companies are aware of their responsibility in this respect and provide financial and logistic support to research in new methods of contraception. Over the last 10 years, clear proofs have been established that exogenous administration of sexual steroids is an efficient and reversible contraception method through inhibition of spermatogenesis. The results of some non-hormonal approaches to male contraception have been surprisingly promising and may become a basis for the development of new methods of male contraception. However, none of the so far published methods of contraception is 100 % effective and applicable to all men in the world population with the guarantee of full reversibility of induced infertility. Vasectomy thus continues to be the only safe and reliable method.

Key words:
male contraception, testosterone, progestins, spermatogenesis, vasectomy

Zdroje

1. United Nations Population Fund (UNFPA) 1998. Levels and trends of contraceptive use as assessed in 1998. New York: UNFPA. http://www.un.org/esa/population/pubsarchive/contraceptives1998/contraceptives1998.htm.

2. (a) Martin CW, Anderson RA, Cheng L et al. Potential impact of hormonal male contraception: crosscultural implications for development of novel preparations. Hum Reprod 2000; 15: 637-45.

(b) Glasier AF, Anakwe R, Everington D et al. Would women trust their partners to use a male pill? Hum Reprod 2000; 15: 646-649.

3. Heinemann K, Saad F, Wiesemes M et al. Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod 2005; 20: 549-556.

4. Poršová-Dutoit I. Mužská hormonální antikoncepce. Vnitř Lék 2006; 52: 1077-1084.

5. (a) WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 1990; 336: 955-959.

(b) WHO Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril 1996; 65: 821-890.

6. Gu YQ, Wang XH, Xu D et al. A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab 2003; 88: 562-568.

7. von Eckardstein S, Noe G, Brache V et al. A clinical trial of 7-alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J Clin Endocrinol Metab 2003; 88: 5232-5239.

8. Meriggiola MC, Farley TM, Mbizvo MT. A review of androgenprogestin regimens for male contraception. J Androl 2003; 24: 466-483.

9. (a) Alvarez-Sanchez F, Faundes A, Brache V et al. Attainment and maintenance of azoospermia with combined monthly injections of depot medroxyprogesterone acetate and testosterone enanthate. Contraception 1977; 15: 635-648.

(b) Frick J, Danner C, Kunit G et al. Spermatogenesis in men treated with injections of medroxyprogesterone acetate combined with testosterone enanthate. Int J Androl 1982; 5: 246-252.

10. Meriggiola MC, Costantino A, Cerpolini S et al. Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men. Clin Endocrinol Metab 2003; 88: 5818-5826.

11. The World Health Organization: http://www. who.int/reproductivehealth/rhl/a05104.html.

12. Gui YL, He CH, Amory JK et al. Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in chinese men. J Androl 2004; 25: 720-727.

13. Kinniburgh D, Zhu H, Cheng RA et al. Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men. Hum Reprod 2002; 17: 1490-1501.

14. Hair WM, Kitteridge K, O'Connor DB et al. A novel male contraceptive pill-patch combination: oral desogestrel and transdermal testosterone in the suppression of spermatogenesis in normal men. J Clin Endocrinol Metab 2001; 86: 5201- 5209.

15. Brady BM, Walton M, Hollow N et al. Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception. Hum Reprod 2004; 19: 2658-2667.

16. Chandra A. Surgical sterilization in the United States, prevalence and characteristics, 1965-95. Vital Health Stat 1998; 23: 1-33.

17. Davis LE, Stockton MD. No-scalpel vasectomy. Prim Care 1997; 24: 433-461.

18. Kirby D, Utz W, Parks P. An implantable ligation device that achieves male sterilization without cutting the vas deferens. Urology 2006; 67: 807-811.

19. Song L, Gu Y, Lu W et al. A phase II randomized controlled trial of a novel male contraception, an intra-vas device. Int J Androl 2006; 29: 489-495.

20. Hoesl CE, Saad F, Pöppel M et al. Reversible, non-barrier male contraception: status and prospects. Eur Urol 2005; 48: 712-723.

21. Meng GD, Zhu JC, Chen ZW et al. Recovery of sperm production following the cessation of gossypol treatment: a two-centre study in China. Int J Androl 1988; 11: 1-11.

22. Lue Y, Sinha Hikim AP, Wang C et al. Triptolide: a potential male contraceptive. J Androl 1998; 19: 479-486.

23. Anderson RA, Baier DT. Male Contraception. Endocr Rev 2002; 23: 735-762.